ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1524

Thrombocytopenia and Systemic Lupus Erythematosus: A Meta-analysis of Observational Studies

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1039

Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1467

Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1209

Time to Knee Replacement by Kellgren-Lawrence Grade and Presence of Frequent Knee Pain in Two Large and Diverse Longitudinal Cohorts: Data from MOST and OAI

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1492

Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0946

Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1507

To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1378

Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1628

Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1010

Total Cost Risk Scores and Barrier Categories in Patients with Axial Spondyloarthritis and Associated Factors

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1260

Toward a Treat-to-target Strategy in Juvenile Dermatomyositis: Seeking for Suitable Targets and Optimal Timing of Their Achievement

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1494

Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0940

Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0967

Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1457

Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial

SpA Including PsA – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].